Cancer neoepitopes

Abstract

Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in themanufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.

Description

[0001] This application claims co-pending U.S. Provisional Application Serial No. 62 / 178956 filed April 23, 2015 and co-pending U.S. Provisional Application Serial No. 62 / 159145 filed May 8, 2015 Priority, both applications are hereby incorporated by reference. technical field [0002] The field of the invention is cancer neoepitopes, in particular the identification of neoepitopes and their use in the generation of neoepitope-specific antibodies, and the use of neoepitopes and neoepitope-specific antibodies in prophylaxis and therapy the use of. Background technique [0003] The Background Description includes information that may be helpful in understanding the present invention. The Background Description is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, nor is any publication explicitly or implicitly referenced to be prior art. [0004] It is well known in the art that most, if not all, neoplast...

AI Technical Summary

Problems solved by technology

In practice, routine production of monoclonal antibodies against a single antigen typically takes months

Images